BioSpace News Archive

Harmony Biosciences Holdings, Inc. today announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS), at the 2023 Foundation for Prader-Willi Research (FPWR) Symposium and Family Conference.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes.

Evaxion Biotech A/S announced that the Company received a letter on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550.

Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023.

Dyadic International, Inc. announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc., to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.

Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the Company has resubmitted the Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™, the company’s on-body injector presentation of UDENYCA® (pegfilgrastim-cbqv), to the U.S. Food and Drug Administration (FDA) for review.

Tenaya Therapeutics, Inc. today announced that the first patient has been dosed with TN-201 gene therapy for the treatment of Myosin Binding Protein C3 (MYBPC3) -associated HCM in the MyPeak-1 Phase 1b clinical trial at the Cleveland Clinic.

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market.

Vistagen today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023 in New York City, New York.